squiffy2
09-19-2008, 04:45 AM
http://www.msrc.co.uk/images/gallery/img_medi.jpg
Data from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis (MS) was presented in two poster presentations at the World Congress for Treatment and Research in MS being held in Montreal, Canada.
The first presentation entitled "Clinical Effect of the Neuroprotectant MN-166 in Relapsing Forms of MS: Year 2 Data" (Poster 48), given by Dr. Richard Gammans, Chief Development Officer of MediciNova, reported that MN-166 treatment resulted in positive findings on three independent measures indicative of a potential disease-progression modifying effect. The poster can be accessed at: http://www.medicinova.com/MN-166-Relapsing-MS.html. The findings include:
* Sustained disability progression was significantly less likely (by
approximately 50 percent) in those patients receiving MN-166 at
either 30 or 60 mg per day for 24 months than in those patients
receiving the drug for 12 months (p=0.026). Sustained disability
progression was measured as a greater than or equal to 1.0 point
increase from baseline in the Expanded Disability Status Scale
(EDSS) score for four consecutive months. This positive clinical
finding was corroborated by positive findings on two separate
radiologic measures.
* The Phase II clinical trial demonstrated that the significant
reduction in brain volume loss (p=0.035), as measured by cranial
magnetic resonance imaging (MRI) scans, observed after 12 months
in patients treated with 60 mg per day of MN-166 compared to
placebo was again demonstrated in year two of the study. Brain
volume loss was significantly less (p=0.030) in patients who
received 60 mg per day of MN-166 for 24 months compared to the
other treatment groups......................
For the full report please go to MSRC: MS Research News : Drugs : MN-166 (Ibudilast) (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1311)
Data from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis (MS) was presented in two poster presentations at the World Congress for Treatment and Research in MS being held in Montreal, Canada.
The first presentation entitled "Clinical Effect of the Neuroprotectant MN-166 in Relapsing Forms of MS: Year 2 Data" (Poster 48), given by Dr. Richard Gammans, Chief Development Officer of MediciNova, reported that MN-166 treatment resulted in positive findings on three independent measures indicative of a potential disease-progression modifying effect. The poster can be accessed at: http://www.medicinova.com/MN-166-Relapsing-MS.html. The findings include:
* Sustained disability progression was significantly less likely (by
approximately 50 percent) in those patients receiving MN-166 at
either 30 or 60 mg per day for 24 months than in those patients
receiving the drug for 12 months (p=0.026). Sustained disability
progression was measured as a greater than or equal to 1.0 point
increase from baseline in the Expanded Disability Status Scale
(EDSS) score for four consecutive months. This positive clinical
finding was corroborated by positive findings on two separate
radiologic measures.
* The Phase II clinical trial demonstrated that the significant
reduction in brain volume loss (p=0.035), as measured by cranial
magnetic resonance imaging (MRI) scans, observed after 12 months
in patients treated with 60 mg per day of MN-166 compared to
placebo was again demonstrated in year two of the study. Brain
volume loss was significantly less (p=0.030) in patients who
received 60 mg per day of MN-166 for 24 months compared to the
other treatment groups......................
For the full report please go to MSRC: MS Research News : Drugs : MN-166 (Ibudilast) (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1311)